Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403181 | 0.81 | EPHX2 (0.41) | EPHX2AKR1C3CYP2C9TBXAS1HPGD | |
| SCHEMBL2405935 | 0.81 | ESR1 (0.43) | AKR1C3 | |
| SCHEMBL2405650 | 0.81 | MEN1 (0.52) | EPHX2HPGDMEN1KMT2A | |
| SCHEMBL2405652 | 0.81 | MEN1 (0.52) | EPHX2HPGDMEN1KMT2A | |
| SCHEMBL2405937 | 0.81 | EPHX2 (0.37) | EPHX2AKR1C3CYP2C9TBXAS1CCKBR | |
| SCHEMBL2403178 | 0.70 | KMT2A (0.65) | EPHX2HPGDMEN1KMT2A | |
| SCHEMBL2404960 | 0.69 | HDAC6 (0.55) | EPHX2AKR1C3TBXAS1HPGDMEN1 | |
| SCHEMBL2404962 | 0.69 | HDAC6 (0.55) | EPHX2AKR1C3TBXAS1HPGDMEN1 | |
| SCHEMBL25393785 | 0.65 | CYP2C9 (0.55) | CYP2C9MEN1KMT2A | |
| SCHEMBL7764222 | 0.64 | TBXAS1 (0.68) | AKR1C3TBXAS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | EPHX2 2868/4885AKR1C3 847/4885CYP2C9 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.